T

Tandem Diabetes Care

Develops subcutaneous insulin pumps and software

Principal Site Reliability Engineer

Full-TimeUpdated on 10/1/2026
$165k - $185k/yr+ Bonus
Senior, Expert
Bachelor's
Remote in USA
Remote

About the job

Requirements
  • Demonstrated experience leading production support and incident management for production systems, including incident command during high-severity events.
  • Strong grounding in Site Reliability Engineering principles, including service-level indicators, service-level objectives, blameless postmortems, toil reduction, and treating reliability as an engineering discipline.
  • Demonstrated experience owning on-call strategy, including rotation design, alert tuning, and escalation.
  • Expertise with Terraform or comparable infrastructure as code at scale, including module design, state management, and policy-as-code guardrails.
  • Hands-on experience building continuous integration and continuous delivery pipelines with reliability guardrails using tools such as GitHub Actions, Octopus Deploy, or Azure DevOps.
  • Deep experience with at least one major cloud platform, such as AWS, Azure, or Google Cloud Platform, and with containerization and orchestration using Docker and Kubernetes.
  • Working knowledge of observability tooling such as Prometheus, Grafana, Datadog, CloudWatch, ELK, or OpenSearch, and experience using it for service-level-objective-based alerting.
  • Experience designing and testing disaster recovery, including backup and restore, failover, and recovery time objective and recovery point objective validation.
  • Working knowledge of cloud security and compliance practices, including identity and access management, network segmentation, encryption, vulnerability management, patch management, and cloud cost optimization.
  • Proficiency in at least one scripting or programming language, such as Python, Go, or Bash, for automation and tooling.
  • Ability to actively leverage artificial intelligence to enhance, automate, and optimize internal tooling and system integrations.
Responsibilities
  • Lead day-to-day production support, including intake, triage, prioritization, escalation, queue health, and change execution.
  • Establish consistent support practices across a distributed team, including shift handoffs, ticket quality standards, and clear ownership of open issues.
  • Lead incident management end to end, including incident command, stakeholder communication, and blameless postmortems with corrective actions tracked to closure.
  • Coordinate response activities for production security incidents with Security teams to contain threats, restore services, validate controls, and implement corrective actions.
  • Own on-call strategy, including rotation design, escalation paths, alert tuning, and tooling such as PagerDuty and New Relic.
  • Build runbooks that standardize responses to common failure modes and enable first-line resolution by engineers who did not build the system.
  • Define and own service-level indicators and service-level objectives for critical services to guide monitoring, alerting, and reliability priorities.
  • Drive reductions in mean time to detect and mean time to resolve through improved instrumentation, alerting, diagnostics, and automation.
  • Convert recurring support burden into permanent fixes, automation, or documentation.
  • Establish and maintain technology currency and lifecycle management practices for production platforms, including cloud services, Kubernetes clusters, operating systems, runtimes, and infrastructure components.
  • Own business continuity and disaster recovery readiness for production platforms, including backup and recovery strategies, recovery testing, failover capabilities, recovery runbooks, and adherence to recovery time and recovery point objectives.
  • Lead infrastructure automation with Terraform so infrastructure is version-controlled, modular, reusable, and auditable.
  • Eliminate toil through automation and reduce manual, repetitive operational work across the team.
  • Add reliability guardrails to continuous integration and continuous delivery pipelines, including automated rollback, change-risk checks, and progressive delivery.
  • Maintain production systems in accordance with applicable regulatory and compliance requirements and keep operational controls audit-ready.
  • Maintain documentation and evidence for business continuity and disaster recovery controls, including recovery testing results, remediation plans, and audit artifacts.
  • Partner with Security, Quality, and Compliance teams to maintain regulatory compliance, support internal and external audits, and resolve audit findings and remediation activities.
  • Grow the capability of Site Reliability Engineering and DevOps engineers, including consulting-partner engineers, through pairing, design and code review, and incident debriefs.
  • Communicate in a documentation-first manner suited to a distributed, multi-time-zone team.
  • Partner with software engineering, quality assurance, and architecture teams to embed reliability and operability into the development lifecycle.
  • Inform capacity planning and scaling strategy with the Test team and introduce proactive resilience testing such as game days once baseline support and observability are stable.
  • Partner with application, architecture, and business stakeholders to align business continuity and disaster recovery capabilities with application requirements and recovery objectives.
  • Support cloud cost optimization through rightsizing, reserved capacity, and observability spend governance.
  • Ensure work complies with company policies, including Privacy and Health Insurance Portability and Accountability Act requirements and other regulatory, legal, and safety requirements.
Desired Qualifications
  • Experience in Food and Drug Administration and International Organization for Standardization regulated industries and with agile methodologies.
  • Relevant cloud certifications, such as AWS, Azure, or Google Cloud Platform Professional or Architect-level certifications.
  • A Bachelor of Science degree in Computer Science or an equivalent combination of education and applicable job experience, including technical school training and certifications in networks, servers, and cloud infrastructure.
  • Ten or more years in Site Reliability Engineering, DevOps, or infrastructure engineering, including leading production support, incident management, and postmortem practice; managing production cloud infrastructure as code at scale; operating and improving production continuous integration and continuous delivery pipelines; designing, executing, and testing disaster recovery plans; and partnering with security teams on production security and compliance posture.
  • Two or more years mentoring or technically leading other engineers, including remote, offshore, or partner-contracted engineers.

About the company

Tandem Diabetes Care designs and sells insulin pumps and related software for people with diabetes. Its flagship product is the t:slim X2 insulin pump, a subcutaneous device that delivers insulin and can work with other diabetes management devices through interoperable technology. A key feature is Basal-IQ, which uses continuous glucose monitoring data to predict low blood sugar and pause insulin delivery to prevent hypoglycemia. The company generates revenue from selling pumps and accessories like infusion sets and cartridges, as well as software updates and subscriptions for advanced management features, creating recurring income. Tandem differentiates itself with interoperable hardware and software that aim to simplify diabetes care and integrate with other devices, not just sell a single pump. Its goal is to improve diabetes management and quality of life by providing user-friendly, connected insulin delivery and management solutions for patients aged six and older.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

2006

Get referred to Tandem Diabetes Care

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 28, 2026 international Mobi rollout added twelve markets and immediate shipment.
  • Q2 2026 revenue reached $254.6 million; full-year guidance stayed at $1.065-1.085 billion.
  • Pharmacy sales hit 10% of U.S. sales in Q2 2026, improving recurring revenue.

What critics are saying

  • FDA recall Z-0427-2026 on Mobi software exposed Malfunction 12; trust damage persists through 2026.
  • Class 2 t:slim X2 recall on January 30, 2026 showed translation-control failures.
  • Insulet and Dexcom pressure pricing, while Tandem still carries $300 million 2032 notes.

What makes Tandem Diabetes Care unique

  • Tandem Mobi is the world’s smallest durable AID system, launched September 2026.
  • Control-IQ+ now covers pregnancy in type 1 diabetes and adults with type 2.
  • Remote software updates and interoperable CGM support keep t:slim X2 and Mobi relevant.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Holidays

401(k) Company Match

Remote Work Options

Hybrid Work Options

Employee Stock Purchase Plan

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↑ 0%

2 year growth

↑ 1%
Business Wire
Sep 28th, 2026
Tandem Mobi automated insulin delivery system launches in 12 European markets

Tandem Diabetes Care has launched its Tandem Mobi automated insulin delivery system in 12 countries outside the United States. The company is now taking orders and shipping to eligible customers in Belgium, the Czech Republic, Denmark, Finland, Germany, Israel, Italy, Luxembourg, Spain, Sweden, Switzerland, and the United Kingdom. Tandem Mobi is described as the world's smallest durable automated insulin delivery system. It uses Control-IQ+ technology and a Dexcom G7 continuous glucose monitoring system to predict glucose levels 30 minutes ahead and automatically adjust insulin delivery every five minutes. The system offers mobile app control through compatible iPhones, multiple wear options, and a 200-unit cartridge. Android compatibility is expected in select countries in 2027.

6ix
Sep 28th, 2026
Tandem Mobi automated insulin delivery system now available in twelve international markets.

Tandem Mobi automated insulin delivery system now available in twelve international markets. Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world's smallest, durable automated insulin delivery system for people living with diabetes,[1] is now available in 12 countries outside the United States. The company is now taking orders and shipping to eligible customers in Belgium, the Czech Republic, Denmark, Finland, Germany, Israel, Italy, Luxembourg, Spain, Sweden, Switzerland, and the United Kingdom. Tandem Mobi, the world's smallest, durable insulin delivery system, now shipping in multiple international markets. Tandem Mobi is powered by Control-IQ+ technology, the predictive algorithm that automates insulin delivery. The system uses a Dexcom G7 continuous glucose monitoring system to predict glucose levels 30 minutes ahead and automatically adjust insulin delivery every 5 minutes to help reduce high and low blood sugar. Tandem Mobi also offers multiple wear options, mobile app control through a compatible, personal iPhone,[*] and a 200-unit cartridge. Control-IQ+ technology has been evaluated in studies of people with type 1 diabetes, type 1 diabetes during pregnancy, and type 2 diabetes, including studies published by the and the, with results showing immediate and sustained glycemic improvements, including more time in range and improved sleep. J NextS SaveEsc Close Scroll

The Diabetes Times
Sep 10th, 2026
Abbott's Libre established as the "most connected CGM in the world"

Abbott's Libre established as the "most connected CGM in the world" 10th September 2026 Abbott today announced the integration of its FreeStyle Libre 3 Plus sensor with Insulet's Omnipod(R) 5 Automated Insulin Delivery (AID) System in the UK, further expanding connected care options for people living with Type 1 diabetes who use a Libre sensor. The full UK availability of this latest integration builds on Abbott's FreeStyle Libre 3 Plus sensor and Tandem Diabetes Care's t:slim X2 insulin pump integration, which became available this summer. Based on the number of pump users having the ability to connect with Libre technology globally these latest partnerships establish Libre as the most connected continuous glucose monitoring (CGM) technology in the world*, providing users with access to more pump options globally than any other CGM. Today, in the UK, Abbott's connected diabetes management solutions are compatible with the following automated insulin delivery systems, or insulin pumps: * Insulet's Omnipod(R) 5 with both the FreeStyle Libre 3 Plus and the FreeStyle Libre 2 Plus sensors * Tandem Diabetes Care's t:slim X2 insulin pump with the FreeStyle Libre 3 Plus sensor * mylife Diabetes Care's YpsoPump insulin pump with the FreeStyle Libre 3 Plus sensor * MiniMed(TM) 780G system with the Instinct sensor, made exclusively by Abbott and distributed by Medtronic Hybrid closed loop systems like these combine a CGM with an insulin pump to automatically adjust insulin delivery based on glucose readings. They help people spend less time managing their condition and more time focusing on the things that matter to them. Libre technology provides real-time, personalised insights to help people understand how food, activity and medications affect their bodies. The latest Libre innovation is the world's first dual glucose-ketone sensor, which monitors glucose and helps detect rising ketone levels that can lead to diabetic ketoacidosis, a serious diabetes-related complication. Graeme Scott, 58, from Angus, who lives with type 1 diabetes said: "My life has changed immensely for the better since starting on a hybrid closed loop system. Having my sensor and pump working together gives me greater confidence and flexibility day-to-day, helping reduce the burden of managing diabetes. The technology means I spend less time thinking about my glucose levels and more time focusing on the things I enjoy. I'm running my own life instead of letting diabetes run it for me." Julia Hammac, General Manager for Abbott's diabetes care business in the UK, said: "For people living with type 1 diabetes, having access to technologies that work seamlessly together can make a meaningful difference to day-to-day diabetes management. By expanding our hybrid closed loop partnerships, we're giving people more choice in how they manage their condition and helping make advanced diabetes technologies more accessible through connected care solutions." Hilary Nathan, Director of Policy and Communications at Breakthrough T1D said: "For many people living with type 1 diabetes, technology is part of everyday life. Having choice really matters. Everyone's experience of diabetes is different, and what works brilliantly for one person may not be right for another. We welcome developments that give people more options and greater flexibility in how they manage their condition, allowing them to choose technology that fits their individual needs, preferences and lives. Ultimately, we want to see a technology landscape shaped around the people who use it, with the freedom to choose the tools that work best for them and today's announcement helps us take one step further towards that." *Data on File, Abbott Diabetes Care

Yahoo Finance
Sep 9th, 2026
Tandem Diabetes rises 59% as Mobi tubeless pump awaits FDA clearance

Tandem Diabetes Care is positioned for growth through expanding product choices and a pay-as-you-go reimbursement model that lowers upfront costs whilst supporting higher recurring supply revenue. The company submitted a 510(k) for its Mobi tubeless pump targeting a 2026 launch and received FDA approval to begin a pivotal study for its fully closed-loop AIDANET programme. In the second quarter of 2026, pharmacy sales reached 10% of US sales, up from 6% in the first quarter, with formulary coverage at approximately 45%. Tandem reaffirmed its 2026 sales guidance of $1.065-$1.085 billion. The stock has risen 59% over the past year, against a 5.4% industry decline. The company holds a Zacks Rank #3 (Hold) with a market capitalisation of $1.05 billion.

Yahoo Finance
Aug 15th, 2026
Tandem Diabetes meets Q2 expectations but shares fall on US pump shipment concerns

Tandem Diabetes met Wall Street's revenue and profit expectations in Q2, reporting revenue of $254.6 million versus analyst estimates of $253.8 million. However, the market responded negatively, likely reflecting investor caution around US pump shipment pace and the company's business model transition. Management highlighted stronger pump shipment growth internationally and early traction from its new pharmacy channel in the US. CEO John Sheridan emphasised operational efficiencies and expanded access to technology contributed to improved margins. The company reconfirmed its full-year revenue guidance of $1.08 billion at the midpoint. Operating margin improved to -5.4%, up from -21.5% in the same quarter last year. Analyst questions focused on pharmacy transition progress, type 2 diabetes retention trends, and the timeline for Mobi tubeless FDA clearance and launch.